Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has filed two provisional patent applications with the United States Patent and Trademark Office (“USPTO”) for innovative processes for synthesizing ibogaine. According to the announcement, MINDCURE’s pharmaceutical-grade ibogaine would provide researchers access to a sustainable, high-quality, reliable and consistent supply of the psychedelic drug, ibogaine. The company is currently evaluating which of the two processes to develop first. MCURF has already completed the first stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research and is now preparing to begin stage two of the manufacturing process. Typically ibogaine is extracted from the iboga plant by a process that can impact the consistency required of a psychedelic drug for research purposes. MINDCURE’s fully synthetic production routes could provide access to an ibogaine supply that offers the consistency required for research. “I believe that the demand for synthetic ibogaine will increase dramatically as research in this field continues to grow. Researchers need access to a standardized, high-quality supply of ibogaine that ensures consistent dosing and reliable results,” said MINDCURE’s president and CEO Kelsey Ramsden in the press release.”We look forward to working with researchers in the medical psychedelic industry and ultimately supplying the broader market to treat all indications supported by research, with an eye to treating addiction at the forefront.”
To view the full press release, visit https://ibn.fm/WkJfQ
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.